risedronic acid has been researched along with Cardiovascular Diseases in 4 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feldbrin, Z | 1 |
| Luckish, A | 2 |
| Shargorodsky, M | 2 |
| Cernes, R | 1 |
| Boaz, M | 1 |
| Gavish, D | 1 |
| Matas, Z | 1 |
| Fux, A | 1 |
| Ye, Y | 1 |
| Hu, SJ | 1 |
| Goldstein, MR | 1 |
2 trials available for risedronic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Effects of long-term risedronate treatment on serum ferritin levels in postmenopausal women with osteoporosis: the impact of cardiovascular risk factor load.
Topics: Aged; Bone Density Conservation Agents; C-Reactive Protein; Cardiovascular Diseases; Female; Ferriti | 2016 |
Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.
Topics: Aged; Arteries; Biomarkers; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; D | 2008 |
2 other studies available for risedronic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
Topics: Apolipoproteins; Arteries; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; Et | 2009 |
Bisphosphonate therapy and vascular calcification.
Topics: Blood Vessels; Calcification, Physiologic; Calcinosis; Calcium Channel Blockers; Cardiovascular Dise | 2000 |